Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention | Zendy

Anthony T. Podany | Zendy; Yajing Bao | Zendy; Susan Swindells | Zendy; Richard E. Chaisson | Zendy; Janet W. Andersen | Zendy; Thando Mwelase | Zendy; Khuanchai Supparatpinyo | Zendy; Lerato Mohapi | Zendy; Amita Gupta | Zendy; Constance A. Benson | Zendy; Peter Kim | Zendy; Courtney V. Fletcher | Zendy

Open Access

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention

Author(s) -

Anthony T. Podany,

Yajing Bao,

Susan Swindells,

Richard E. Chaisson,

Janet W. Andersen,

Thando Mwelase,

Khuanchai Supparatpinyo,

Lerato Mohapi,

Amita Gupta,

Constance A. Benson,

Peter Kim,

Courtney V. Fletcher

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ464

Subject(s) - rifapentine , efavirenz , medicine , isoniazid , tuberculosis , regimen , pharmacokinetics , pharmacology , rifamycin , pharmacodynamics , elvitegravir , human immunodeficiency virus (hiv) , virology , concomitant , latent tuberculosis , mycobacterium tuberculosis , antiretroviral therapy , viral load , antibiotics , microbiology and biotechnology , pathology , biology

Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeutic concentrations of antiretroviral drugs. We studied the interaction of efavirenz with daily rifapentine and isoniazid in human immunodeficiency virus (HIV)-infected individuals receiving a 4-week regimen to prevent tuberculosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research